Navidea Biopharmaceuticals (NASDAQ:NAVB) Rating Reiterated by HC Wainwright

Share on StockTwits

Navidea Biopharmaceuticals (NASDAQ:NAVB)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Friday, Zacks.com reports.

Navidea Biopharmaceuticals (NASDAQ:NAVB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) EPS for the quarter. The firm had revenue of $0.24 million for the quarter.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages.

Featured Article: What are the benefits of a portfolio tracker?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

G Bradley Cole Sells 10,000 Shares of EXACT Sciences Co.  Stock
G Bradley Cole Sells 10,000 Shares of EXACT Sciences Co. Stock
Ault & Company, Inc. Acquires 660,667 Shares of DPW Holdings Inc  Stock
Ault & Company, Inc. Acquires 660,667 Shares of DPW Holdings Inc Stock
Kadant Inc.  Chairman Jonathan W. Painter Sells 7,200 Shares
Kadant Inc. Chairman Jonathan W. Painter Sells 7,200 Shares
AtriCure Inc.  CEO Sells $850,000.00 in Stock
AtriCure Inc. CEO Sells $850,000.00 in Stock
Forty Seven Inc  Director Ravindra Majeti Sells 25,000 Shares
Forty Seven Inc Director Ravindra Majeti Sells 25,000 Shares
Kevin M. Murai Sells 5,800 Shares of SYNNEX Co.  Stock
Kevin M. Murai Sells 5,800 Shares of SYNNEX Co. Stock


© 2006-2020 Ticker Report